LOGO
LOGO

Corporate News

Methode Electronics Slashes FY13 Forecast - Quick Facts

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Methode Electronics Inc. (MEI) said it has updated its fiscal 2013 revenue guidance in the range of $470 million - $500 million and earnings per share guidance of $0.45 - $0.60. This compares with the prior revenue guidance in the range of $495 million - $525 million and earnings per share guidance of $0.66 - $0.81. This guidance exclude income from the legal settlement previously announced on August 30, 2012, the company said.

The updated estimates reflect a customer-driven temporary launch delay of a significant new laundry program at the Company's TouchSensor business coupled with softening sales demand in its European Automotive operations due to weakening economic conditions in Europe. Neither of these factors impacted Methode's first-half fiscal 2013 results.

President and CEO, Donald Duda, said, "Although we are disappointed that Fiscal 2013 revenue and earnings will not be as strong as we originally anticipated, we believe revenue this fiscal year will still improve and earnings per share will improve 105 percent to 173 percent over Fiscal 2012. Additionally, we anticipate growing revenues to $640 million and $720 million in our Fiscal Years 2014 and 2015, which is higher than our previous outlook."

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19